The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials
Autor: | Chang-hong Duan, Ting-fang Dong, Qing-lin Fu, Ye-min Wang, Fang Ai, Bao-zhe Jin, Yi-zhong Lu |
---|---|
Rok vydání: | 2011 |
Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.medical_treatment Antineoplastic Agents Toxicology Antioxidants law.invention Melatonin Randomized controlled trial law Internal medicine Neoplasms medicine Adjuvant therapy Humans Pharmacology (medical) Adverse effect Radiation Injuries Survival rate Randomized Controlled Trials as Topic Pharmacology Chemotherapy business.industry Remission Induction Cancer medicine.disease Combined Modality Therapy Surgery Radiation therapy Survival Rate business medicine.drug |
Zdroj: | Cancer chemotherapy and pharmacology. 69(5) |
ISSN: | 1432-0843 |
Popis: | Recently, melatonin has been associated with cancer both in vitro and in vivo. However, the value of melatonin in the treatment of cancer remains disputable. Hence, we performed a systematic review of randomized controlled trials (RCTs) of melatonin in solid tumor cancer patients and observed its effect on tumor remission, 1-year survival, and side effects due to radiochemotherapy. An electronic search was conducted using the databases Pubmed, Medline, EMBASE, Cochrane library, and CNKI, from inception to November 2011. Trials using melatonin as adjunct treatment concurrent with chemotherapy or radiotherapy for cancer were included. Pooled relative risk (RR) for the tumor remission, 1-year survival, and radiochemotherapy-related side effects were calculated using the software Revman 5.0. The search strategy identified 8 eligible RCTs (n = 761), all of which studied solid tumor cancers. The dosage of melatonin used in the 8 included RCTs was 20 mg orally, once a day. Melatonin significantly improved the complete and partial remission (16.5 vs. 32.6%; RR = 1.95, 95% CI, 1.49–2.54; P |
Databáze: | OpenAIRE |
Externí odkaz: |